Literature DB >> 10614618

Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2.

S E Blutt1, T J McDonnell, T C Polek, N L Weigel.   

Abstract

While the role of vitamin D in bone and mineral metabolism has been investigated extensively, the role of the vitamin D receptor in other tissues is less well understood. 1,25-Dihydroxyvitamin D3 (calcitriol) can act as a differentiating agent in normal tissues and can inhibit the growth of many cancer cell lines including LNCaP prostate cancer cells. We have shown previously that calcitriol causes LNCaP cell accumulation in the G0/G1 phase of the cell cycle. In this study, we demonstrate that calcitriol also induces apoptosis of LNCaP cells. The calcitriol-induced apoptosis is accompanied by a down-regulation of Bcl-2 and Bcl-X(L) proteins, both of which protect cells from undergoing apoptosis. Other proteins important in apoptotic control, Bax, Mcl-1, and Bcl-X(S), are unaffected by calcitriol treatment. We find that overexpression of Bcl-2 blocks calcitriol-induced apoptosis and reduces, but does not eliminate, calcitriol-induced growth inhibition. We conclude that both regulation of cell cycle and the apoptotic pathway are involved in calcitriol action in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10614618     DOI: 10.1210/endo.141.1.7289

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  40 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

2.  Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate.

Authors:  Pavlo L Kovalenko; Zhentao Zhang; Jun-Ge Yu; Yan Li; Steven K Clinton; James C Fleet
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-11

3.  The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells.

Authors:  Irene Bobilev; Victoria Novik; Itai Levi; Ofer Shpilberg; Joseph Levy; Yoav Sharoni; George P Studzinski; Michael Danilenko
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

4.  Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.

Authors:  John M Baust; Daniel P Klossner; Anthony Robilotto; Robert G Vanbuskirk; Andrew A Gage; Vladimir Mouraviev; Thomas J Polascik; John G Baust
Journal:  BJU Int       Date:  2011-08-26       Impact factor: 5.588

5.  Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

Authors:  Yaw A Nyame; Adam B Murphy; Diana K Bowen; Gregory Jordan; Ken Batai; Michael Dixon; Courtney M P Hollowell; Stephanie Kielb; Joshua J Meeks; Peter H Gann; Virgilia Macias; Andre Kajdacsy-Balla; William J Catalona; Rick Kittles
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

Review 6.  The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms.

Authors:  Meis Moukayed; William B Grant
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

7.  Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model.

Authors:  Rahul Ray; Mara Banks; Hilal Abuzahra; Vikram J Eddy; Kelly S Persons; M Scott Lucia; James R Lambert; Michael F Holick
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

Review 8.  Vitamin D metabolism and action in the prostate: implications for health and disease.

Authors:  Srilatha Swami; Aruna V Krishnan; David Feldman
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

9.  Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance.

Authors:  David T Marshall; Stephen J Savage; Elizabeth Garrett-Mayer; Thomas E Keane; Bruce W Hollis; Ronald L Horst; Linda H Ambrose; Mark S Kindy; Sebastiano Gattoni-Celli
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

Review 10.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.